SKINDEX-16 for Alopecia Areata (SKINDEX-16 for AA)

Chren MM

Distributed by Mapi Research Trust


Distributed by Mapi Research Trust

Basic description

  • Developed in 2018
  • Other existing "parent" or revised/short versions of the instrument: Skindex (developed in 1996), Skindex-16 (developed in 1997), Skindex-29 (developed in 2001)

Chren MM

Copyright © 2018, The Regents of the University of California. All Rights Reserved.
To measure the effects of skin disease on patients' quality of life
Therapeutic area
  • Skin and Connective Tissue Diseases
  • Pathological Conditions, Signs and Symptoms
Therapeutic indication


Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Information from the author and the review copy

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use


Chren MM

Mary-Margaret Chren, MD
Professor and Chair, Department of Dermatology
Robert N. and Rachelle Buchanan and
A.H. and Lucile Lancaster Chair in Dermatology
Vanderbilt University Medical Center
719 Thompson Lane, Suite 26300
Nashville, TN  37204
Phone: 615-322-0845

Mary-Margaret Chren's publications (PubMed)

Contact information

Mapi Research Trust
27 rue de la Villette
69003 Lyon
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access available translations of the questionnaire directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.


Original language(s)

  • English for the USA


The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

More information on translations

For information on, or permission to use the translations, please contact Mapi Researh Trust